On October 15th, Propanc Biopharma, a biopharmaceutical company that adopts the Ethereum treasury strategy, announced a strategic financing agreement of up to $100 million with the family office Hexstone Capital. Propanc CEO James Nathanielsz said that the financing will accelerate the development of the company's clinical pipeline and plans to grow the value of the digital asset library to $100 million or more in the next 12 months. Hexstone Capital has previously invested in several companies ...
10 月 15 日消息,采用以太坊财库战略的生物制药公司 Propanc Biopharma 宣布与家族办公室 Hexstone Capital 达成最高 1 亿美元的战略融资协议。 Propanc CEO James Nathanielsz 表示,此次融资将加速公司临床管线开发,并计划在未来 12 个月内将数字资产库价值增长至 1 亿美元或以上。Hexstone Capital 此前已投资多家拥有数字资产库的公司,涉及 BTC、ETH、SOL、DOGE 等多种数字资产。 此前消息,九月初...